Results 21 to 30 of about 12,590 (214)

Case of Ibuprofen-Induced Liver Injury

Annals of Internal Medicine: Clinical Cases, 2023
Drug-induced liver injury (DILI) resulting from nonsteroidal anti-inflammatory drugs (NSAIDs) is a rare phenomenon; however, several cases have been reported in the literature and the LiverTox database.
Kirsten Wong, Beda Cha, Simon Wu
doaj   +1 more source

Combinatorial targeting of G‐protein‐coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug‐induced liver injury

Hepatology, EarlyView., 2022
CHIN117 is a dual cysteinyl leukotriene receptor 1 (CYSLTR1) antagonist and G‐protein‐coupled bile acid receptor 1 (GPBAR1) agonist. In the liver, GPBAR1 and CYSLTR1 are coexpressed by liver sinusoidal endothelial cells (LSECs), HSCs, circulating monocytes/macrophages, and liver resident macrophages (Kupffer cells).
Michele Biagioli, Silvia Marchianò, Cristina di Giorgio, Rosalinda Roselli, Martina Bordoni, Rachele Bellini, Bianca Fiorillo, Valentina Sepe, Bruno Catalanotti, Chiara Cassiano, Maria Chiara Monti, Eleonora Distrutti, Angela Zampella, Stefano Fiorucci   +13 more
wiley   +1 more source

Endoplasmic Reticulum Stress and Mitochondrial Stress in Drug-Induced Liver Injury

Molecules, 2023
Drug-induced liver injury (DILI) is a widespread and harmful disease closely linked to mitochondrial and endoplasmic reticulum stress (ERS). Globally, severe drug-induced hepatitis, cirrhosis, and liver cancer are the primary causes of liver-related ...
Sisi Pu, Yangyang Pan, Qian Zhang, Ting You, Tao Yue, Yuxing Zhang, Meng Wang   +6 more
doaj   +1 more source

Computational Approaches for Drug-Induced Liver Injury (DILI) Prediction: State of the Art and Challenges [PDF]

, 2021
Drug-induced liver injury (DILI) is one of the prevailing causes of fulminant hepatic failure. It is estimated that three idiosyncratic drug reactions out of four result in liver transplantation or death. Additionally, DILI is the most common reason for withdrawal of an approved drug from the market.
Béquignon, O.J.M., Pawara, G., Water, B. van de, Cronin, M.T.D., Westen, G.J.P. van   +4 more
openaire   +2 more sources

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle [PDF]

Frontiers in Genetics, 2012
Despite stringent requirements for drug development imposed by regulatory agencies, drug-induced liver injury (DILI) is an increasing health problem and a significant cause for failure to approve drugs, market withdrawal of commercialized medications, and adoption of regulatory measures.
Stephens, Camilla, Lucena, M Isabel, Andrade, Raúl J   +2 more
openaire   +4 more sources

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. [PDF]

, 2012
To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection.
A Habtewold, A Kwara, A Patel, A Tostmann, A Tostmann, A Tostmann, A Turkova, AK Daly, AM Anderson, B Lopman, BS Kappelhoff, C Benichou, C Nyakutira, CJ Hoffmann, CJ Hoffmann, D Voora, DF Wares, E Aklillu, E Aklillu, E Lopez-Lopez, E Ngaimisi, E Ngaimisi, E Pukenyte, Eleni Aklillu, Eliford Ngaimisi, Eric Sandstrom, Ferdinand Mugusi, G Yimer, G Yimer, G Yimer, GJ Dore, GL Dean, JG Stine, JJ Saukkonen, JK Mukonzo, JR Ungo, Juergen Burhenne, K Cohen, Klaus-Dieter Riedel, Lars Lindquist, LK Shipton, M Fiegenbaum, M Nelson, MI Matee, Mohamed Janabi, Muhammad Bakari, N Abrescia, N Soleman, Omary Minzi, P Kuehl, P Ocama, Petros C. Karakousis, R Kalyesubula, R Singla, RA Mirghani, S Russmann, Sabina Mugusi, SC Figueroa, SF Mugusi, V Gounden, W Mankhatitham, Z Desta, ZS Lamar   +62 more
core   +6 more sources

Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor

Frontiers in Pharmacology, 2022
Of the patients infected with coronavirus disease 2019 (COVID-19), approximately 14–53% developed liver injury resulting in poor outcomes. Drug-induced liver injury (DILI) is the primary cause of liver injury in COVID-19 patients.
Jingjing Huang, Zhaokang Zhang, Chenxia Hao, Chenxia Hao, Yuzhen Qiu, Ruoming Tan, Jialin Liu, Xiaoli Wang, Wanhua Yang, Hongping Qu   +9 more
doaj   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Indigenous Herbal Drug (Tinospora Cordifolia) Induced Liver Injury: A Case Report [PDF]

Bengal Physician Journal
Drug-induced liver injury (DILI) is a condition characterized by acute or chronic liver damage following the use of hepatotoxic drugs. It can be classified based on clinical presentation (hepatocellular, cholestasis, or mixed), mechanism of ...
Sounak Kumar Roy, Muniruddin SK, Subham Mondal, Sandipan Mukherjee, Santa Subhra Chatterjee   +4 more
doaj   +1 more source

Hepatic macrophages in drug-induced liver injury

Liver Research, 2019
Drug-induced liver injury (DILI) is a major public health concern. Intrinsic DILI, for example, acetaminophen overdose accounts for half of acute liver failure in the United States.
Zhao Shan, Cynthia Ju
doaj   +1 more source